Compare VENUS REMEDIES with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES CADILA HEALTHCARE VENUS REMEDIES/
CADILA HEALTHCARE
 
P/E (TTM) x -1.1 14.0 - View Chart
P/BV x 0.1 2.3 3.4% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
CADILA HEALTHCARE
Mar-19
VENUS REMEDIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs126432 29.1%   
Low Rs61306 19.9%   
Sales per share (Unadj.) Rs301.8128.6 234.7%  
Earnings per share (Unadj.) Rs-24.918.5 -134.1%  
Cash flow per share (Unadj.) Rs2.524.4 10.4%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs293.3101.5 289.1%  
Shares outstanding (eoy) m12.341,023.74 1.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.8%   
Avg P/E ratio x-3.819.9 -18.9%  
P/CF ratio (eoy) x36.715.1 242.7%  
Price / Book Value ratio x0.33.6 8.8%  
Dividend payout %018.9 0.0%   
Avg Mkt Cap Rs m1,154378,170 0.3%   
No. of employees `0000.912.4 7.4%   
Total wages/salary Rs m39321,241 1.9%   
Avg. sales/employee Rs Th4,026.110,585.0 38.0%   
Avg. wages/employee Rs Th425.01,707.8 24.9%   
Avg. net profit/employee Rs Th-331.81,526.5 -21.7%   
INCOME DATA
Net Sales Rs m3,724131,656 2.8%  
Other income Rs m232,011 1.1%   
Total revenues Rs m3,747133,667 2.8%   
Gross profit Rs m39529,731 1.3%  
Depreciation Rs m3385,986 5.7%   
Interest Rs m3541,935 18.3%   
Profit before tax Rs m-27523,821 -1.2%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m325,303 0.6%   
Profit after tax Rs m-30718,987 -1.6%  
Gross profit margin %10.622.6 46.9%  
Effective tax rate %-11.522.3 -51.6%   
Net profit margin %-8.214.4 -57.1%  
BALANCE SHEET DATA
Current assets Rs m2,63884,981 3.1%   
Current liabilities Rs m2,30573,425 3.1%   
Net working cap to sales %8.98.8 101.9%  
Current ratio x1.11.2 98.9%  
Inventory Days Days13575 181.7%  
Debtors Days Days46110 42.3%  
Net fixed assets Rs m4,871133,493 3.6%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m3,496102,839 3.4%   
Net worth Rs m3,619103,863 3.5%   
Long term debt Rs m1,37439,497 3.5%   
Total assets Rs m7,509234,831 3.2%  
Interest coverage x0.213.3 1.7%   
Debt to equity ratio x0.40.4 99.9%  
Sales to assets ratio x0.50.6 88.5%   
Return on assets %0.68.9 7.1%  
Return on equity %-8.518.3 -46.4%  
Return on capital %1.618.3 8.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m048,404 0.0%   
Fx outflow Rs m51711,593 4.5%   
Net fx Rs m-51736,811 -1.4%   
CASH FLOW
From Operations Rs m51428,823 1.8%  
From Investments Rs m-123-57,387 0.2%  
From Financial Activity Rs m-38718,846 -2.1%  
Net Cashflow Rs m4-7,105 -0.1%  

Share Holding

Indian Promoters % 32.9 74.8 43.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.3 2.2%  
FIIs % 0.6 5.9 9.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 11.0 603.6%  
Shareholders   20,121 44,069 45.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SHASUN PHARMA  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 14, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS